WO2000009116A1 - Ligands de récepteurs du peptide de libération de la gastrine - Google Patents

Ligands de récepteurs du peptide de libération de la gastrine Download PDF

Info

Publication number
WO2000009116A1
WO2000009116A1 PCT/US1999/018469 US9918469W WO0009116A1 WO 2000009116 A1 WO2000009116 A1 WO 2000009116A1 US 9918469 W US9918469 W US 9918469W WO 0009116 A1 WO0009116 A1 WO 0009116A1
Authority
WO
WIPO (PCT)
Prior art keywords
methoxyphenyl
cyano
cyclopentyloxy
ynyl
guanidine
Prior art date
Application number
PCT/US1999/018469
Other languages
English (en)
Inventor
Jia-Ning Xiang
Joseph M. Karpinski
Siegfried B. Christensen, Iv
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of WO2000009116A1 publication Critical patent/WO2000009116A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Definitions

  • the present invention relates to novel GRP receptor ligands, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat chronic kidney disease and prostate cancer.
  • Chronic renal disease is the progressive loss of renal function due to irreversible and progressive glomerular, tubular or interstitial disease.
  • Current therapy includes treatment of underlying disease, control of hypertension, protein restriction and use of angiotensin converting enzyme (ACE) inhibitor, all of which have limited efficacy.
  • ACE angiotensin converting enzyme
  • captopril is the only approved drug for chronic renal failure and its effects are modest. Data from clinical trials on angiotensin II receptor antagonists indicate some degree of effect, however, it is unclear whether they will provide a dramatic improvement over the ACE inhibitors.
  • Carcinoma of the prostate is the most common malignant disease of men in the U.S., and the second most common cause of cancer-related death in men of all ages.
  • Current therapy for prostate cancer involves radical prostatectomy, radiation therapy, and either surgical (orchiectomy) or medical (leuprolide) castration. Surgical or medical castration have had variable success, and cytotoxic chemotherapy is generally not effective. Anti-androgenic therapy has significant side effects, and relapse can occur as a result of the development of hormone-insensitive cells.
  • GRP Gastrin releasing peptide
  • GRP receptors are present in the kidney, and that GRP stimulates mesangial cell proliferation and the expression of extracellular matrix.
  • a peptide receptor antagonist to GRP attenuates these effects.
  • GRP is recognized as an autocrine factor in some cancer cells (Dietrich, 1994; Cuttitta et al., 1985).
  • the effects of GRP on cell proliferation and differentiation have been explored in a number of organ systems.
  • GRP stimulates lipid surfactant secretion by pneumocytes, indicating a role for GRP in development (Asokananthan and Cake, 1996).
  • GRP stimulates proliferation of lung (Cuttitta et al, 1985), breast (Nelson et al., 1991) and prostate (Bologna et al., 1989) carcinoma cells in vitro.
  • lung and prostate cancer cells which proliferate in response to GRP in vitro are inhibited by treatment with GRP antibodies (Maruno and Said, 1993; Shimoda, 1992) and peptide receptor antagonists (Moody et al., 1995).
  • GRP neuromedin B
  • NMB neuromedin B
  • bombesin The amino acid structure of GRP, neuromedin B (NMB), and bombesin are depicted below.
  • GRP and NMB are mammalian peptides which have homology to the amphibian peptide, bombesin. conserveed amino acids are indicated by solid vertical lines.
  • NMB neuromedin B
  • pGlu denotes pyroglutamate
  • NH2 denotes amidated carboxy-terminal residue
  • GRP GRP
  • NMB NMB
  • BRS3 mammalian bombesin receptor
  • BRS3-def ⁇ cient mice generated by target disruption were obese; and developed diabetes and hypertension (Ohki-Hamazaki et al., 1997).
  • the natural ligand for this receptor is not known, the synthetic analogue of bombesin, [D-
  • Phe6, ⁇ -Alal l,Phel3,Nlel4]Bn(6- 14) has been identified as a high affinity agonist for this receptor (Mantey et al., 1997).
  • the natural ligand as well as the involvement of this receptor in renal and prostate diseases are yet to be identified.
  • GRP/NMB Potent nonselective
  • the present invention involves compounds represented by Formula (I) hereinbelow, pharmaceutical compositions comprising such compounds and methods of antagonizing the GRP receptor using these compounds.
  • the present invention further provides novel methods for the synthesis of the present compounds and novel intermediates involves therein.
  • R is selected from the group consisting of C2-C12 alkyl, heteroalkyl and arylalkyl; Ri is selected from the group consisting of hydrogen, OH, halogen, CN, NO2, CF3, CF2H, C j -Cio alkoxy and NR4R5;
  • R2 is aryl which may be unsubstituted or substituted by one or more substituents selected from the group consisting of C j-C ⁇ alkyl, CF3, CF2H, halogen, CO ⁇ ⁇ , CORg, 0(CH 2 ) n C0 2 R6, Cj-Cg alkoxy, CN, N0 2 , OH, and NR 4 R 5 ; aryl may be further substituted by a substituent selected from the group consisting of pyrrolyl, thiazolyl, oxadiazolyl, all of which may be unsubstituted or substituted by Rg; R3 is selected from the group consisting of hydrogen, C2-Cg aminoalkyl and C2-C.5 hydroxy alkyl;
  • R4 and R5 are independently selected from the group consisting of hydrogen, C2-C12 alkyl, heteroalkyl and arylalkyl;
  • Rg is selected from the group consisting of hydrogen, and C j -Cg alkyl;
  • X is selected from the group consisting of NCN, O, S and NH; and
  • n is an integer from 1 to 4.
  • aryl substituents of R are selected from the group consisting of Cj-C2 alkoxy, C1-C4 alkyl, CF3, Cl, and F.
  • Rj is hydogen or CJ-C2 alkoxy.
  • R2 is phenyl.
  • R3 is hydrogen.
  • X is NCN.
  • alkyl refers to an optionally substituted hydrocarbon group joined together by single carbon-carbon bonds.
  • the alkyl hydrocarbon group may be linear, branched or cyclic, saturated or unsaturated.
  • the group is saturated linear or cyclic.
  • aryl may be phenyl, naphthyl, pyridyl, indolyl, thienyl, pyrimidyl.
  • Preferred compounds useful in the present invention include: (+/-)-N-[2-(3-cyclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-ynyl]guanidine, (+/-)-N-cyano-N -[2-(3-cyclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-ynyl]guanidine, (+/-)-N-[2-(3-cyclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-ynyl]thiourea, (+/-)-N-cyano-N'-[2-(3-cyclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-ynyl]-N"- (benzyl)guanidine,
  • More preferred compounds useful in the present invention include: (+/-)-N-[2-(3-cyclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-ynyl]guanidine,
  • the most preferred compounds useful in the present invention include: (+/-)-N-cyano-N'-[2-(3-cyclopentyloxy-4-methoxyphenyl)-4-(3-chlorophenyl)but-3- ynyljguanidine,
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.
  • the present compounds can also be formulated as pharmaceutically acceptable salts and complexes thereof.
  • Pharmaceutically acceptable salts are non-toxic salts in the amounts and concentrations at which they are administered.
  • Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate.
  • Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • Pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, when acidic functional groups, such as carboxylic acid or phenol are present.
  • “diseases" treatable using the present compounds include but are not limited to
  • the present compounds are prepared using the following novel process: which can be prepared by a process comprising:
  • a halide such as cyclopentyl bromide in the presence of a base such as potassium carbonate in a suitable solvent such as N,N-dimethylformamide at 90oC to afford a cyclopentyl aryl ether of Formula (3).
  • a compound of Formula (13) is treated with a base such as sodium hydride followed by addition of di-t-butyl dicarbonate to afford a compound of Formula (14).
  • an amine of Formula (8) can be reacted with diphenyl cyanocarbonimidate to form a compound of Formula (17).
  • Novel intermediates represented by the present invention include:
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the present ligands can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transdermal, or transmucosal administration.
  • oral administration is preferred.
  • the compounds can be formulated into conventional oral dosage forms such as capsules, tablets and liquid preparations such as syrups, elixirs and concentrated drops.
  • injection parenteral administration
  • the compounds of the invention are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution.
  • the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives.
  • detergents may be used to facilitate permeation.
  • Transmucosal administration for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories.
  • the compounds of the invention can be formulated into ointments, salves, gels, or creams, as is generally known in the art.
  • the amounts of various compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC50, EC50, the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are known to those of ordinary skill in the art.
  • Amounts administered also depend on the routes of administration and the degree of oral bioavailability. For example, for compounds with low oral bioavailability, relatively higher doses will have to be administered.
  • the composition is in unit dosage form.
  • a tablet, or capsule may be administered, for nasal application, a metered aerosol dose may be administered, for transdermal application, a topical formulation or patch may be administered and for transmucosal delivery, a buccal patch may be administered.
  • dosing is such that the patient may administer a single dose.
  • Each dosage unit for oral administration contains suitably from 0.01 to 500 mg/Kg, and preferably from 0.1 to 50 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.
  • the daily dosage for parenteral, nasal, oral inhalation, transmucosal or transdermal routes contains suitably from 0.01 mg to 100 mg/Kg, of a compound of Formula(I).
  • a topical formulation contains suitably 0.01 to 5.0% of a compound of Formula (I).
  • the active ingredient may be administered from 1 to 6 times per day, preferably once, sufficient to exhibit the desired activity, as is readily apparent to one skilled in the art.
  • treatment includes, but is not limited to prevention, retardation and prophylaxis of the disease.
  • compositions of Formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges.
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil. olive oil, glycerine or water with a flavoring or coloring agent.
  • a liquid carrier for example, ethanol, peanut oil. olive oil, glycerine or water with a flavoring or coloring agent.
  • any pharmaceutical carrier routinely used for preparing solid formulations may be used.
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
  • a typical suppository formulation comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa- butter or other low melting vegetable waxes or fats or their synthetic analogs
  • Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose. No unacceptable toxological effects are expected when compounds of the present invention are administered in accordance with the present invention.
  • Membrane preparation Human embryonic kidney (HEK 293) cells transfected with rhGRP receptor clone were washed two times with DPBS and scraped in the same buffer. After pelleting by centrifugation, the cells were frozen in liquid nitrogen and thawed on ice.
  • the cell pellet was resuspended in 20 mM Tris HC1, pH 7.5, 5 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 5 ug/mL leupeptin, and 0.1 U/mL aprotinin, and the suspension was homogenized 20 times using a glass dounce homogenizer and centrifuged at 800 x g for 10 min to remove unbroken cells and nuclei. The supernatant was centrifuged at 40,000 x g for 30 min ana" the pellet was resuspended in 50 mM Tris HC1, pH 7.5 and 10 mM MgC ⁇ .
  • Binding of [125I]-bombesin to the membrane preparation was performed in 50 uL assay volume containing 50 mM Tris HC1, pH 7.5, 10 mM MgCl2, and 0.05% bovine serum albumin. Saturation binding experiments were performed with increasing concentrations of [ 125I]-bombesin and 1-2 ug of the membrane protein in the absence (total binding) and presence (non-specific binding) 1 uM cold GRP. Incubations were carried out at 30 °C for 30 min and terminated by rapid vacuum filtration through GF/C filters, and the filters were counted using a gamma counter with 75% efficiency.
  • HEK293 cells transfected with rhGRP receptors grown in T-150 flasks were labeled with [3H]-myoinositol (1 uCi/mL) for 24 hr in inositol-free DMEM without serum.
  • the radioactive medium was removed and the cells were washed once with DPBS++ (DPBS containing 5 mM glucose, 0.2% bovine serum albumin and 10 mM MgCl2) and incubated in 10-15 mL of DPBS++ containing 10 mM LiCl for 10 min at 37 °C.
  • cells (2x105) were pipetted into 12x75 glass tubes which contain indicated concentrations of antagonists or agonists or antagonists plus agonists and the reaction continued for 20 min. The reaction was stopped by adding 50 uL of 100% trichloroacetic acid. Samples were centrifuged, 0.4 mL of supernatant were withdrawn and neutralized with 10 uL of 1 M Tris base and 2 ml of 5 mM Na tetraborate, containing 0.5 mM EDTA. Total inositol phosphates were separated from free inositol using ion exchange chromatography.
  • Example 1 is illustrative of the present invention but not intended to be limiting in any way.
  • Example 1 is illustrative of the present invention but not intended to be limiting in any way.
  • (+/-)-N-r2-(3-cvclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-vnyllguanidine 1 (a) 2,2-dimethyl-5-(3-cyclopentyloxy-4-methoxybenzylidenyl)- 1 ,3-dioxane-4,6-dione A mixture of 3-cyclopentyloxy-4-methoxybenzaldehyde (12.8 g, 0.058 mol), 2,2-dimethyl- l ,3-dioxane-4,6-dione (8.3 g, 0.058 mol), piperidine (1 mL) and HOAc (0.5 mL) in benzene (150 mL) was refluxed for 2h, using a Dean-Stark trap to remove the water that was formed. Hexane (75 mL) was added, the mixture was cooled, and the crystalline product filtered and dried (18.7 g, 93%)
  • H2O (2 mL) was added dropwise to the cold solution, and stirring continued for 0.25 h.
  • the reaction was diluted with H2O, and extracted with Et2 ⁇ .
  • the organic phase was washed with water, was dried (Na2S04), and was filtered.
  • the ether extract was slowly added to refluxing toluene (100 mL), and the solution was heated at 1 lOoC for 0.5 h, and was evaporated.
  • the residue was dissolved in a mixture of dioxane (5 mL), water (3 mL), and cone. HC1 (3 mL), was refluxed for 0.2 h, was cooled and the solid was filtered.
  • Example 1(d) The compound from Example 1(d) (0.1 g, 0.3 mmol) was partitioned between 10% NaOH and EtOAc. The organic phase was dried (K2CO3) and was evaporated. The residue was dissolved in DMF (0.2 mL) and di-boc-thiourea (0.1 g, 0.36 mmol), prepared according the procedure described by Iwanowicz et.al., Synthetic Communications, 23(10), 1993, 1443-5, was added. 2-Chloro-l -methyl pyridinium iodide (0.09 g, 0.36 mmol) and triethylamine (0.09 mL, 0.66 mmol) were added and the mixture was stirred 18 h.
  • (+/-)-N-r2-(3-cvclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-vnvnthiourea 3(a) (+/-)-N-[2-(3-cyclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-ynyl]-N- benzoylthiourea
  • Example 42 (+/-)-N-cvano-N'-[2-(3-cvclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-vnyn-N"-(2- carboxyethvDguanidine
  • a solution of the compound from Example 31 (0.025 g, 0.05 mmol) in 5:5:2 THF/MeOH/H 0 (2 ml) was treated with KOH (0.01 g, 0.15 mmol) and stirred 5 h.
  • the mixture was acidified with 3 N aqueous HC1 and extracted with CH2CI2.
  • the organic extract was dried (MgS04) and was evaporated.
  • the residue was purified by flash chromatography (silica gel, 10% MeOH/ HCl ⁇ ,) to provide the titled compound as a tan foam, 0.007g (30%).
  • MS(ES) m/e 475 [M+H]+.
  • (+/-)-N-r2-(3-cvclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-ynyllurea A mixture of the compound from Example 1(d) (0.05 g, 0.13 mmol) and potassium cyanate (0.022 g, O.l ⁇ mmol) in 2:1 H2O/ACOH (1 mL) was stirred for 8 days. The mixture was diluted with water and was extracted with CH2CI2. The organic extract was dried (MgS ⁇ 4) and was evaporated.
  • (+/-)-3-(3-Cyclopentyloxy-4-methoxyphenyl)-3-trimethylsilylethynylpropionic acid Following the procedure of Example 1 (c), except substituting (+/-)-2,2-dimethyl- 5-([ l-(3-cyclopentyloxy-4-methoxyphenyl)-3-trimethylsilyl]prop-2-yne)- 1 ,3-dioxane-4,6- dione for (+/-)-2,2-dimethyl-5-([ l-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenyl]prop-2- yne)-l,3-dioxane-4,6-dione the titled compound was prepared (78%).
  • (+/-)-4-Amino-3-(3-cyclopentyloxy-4-methoxyphenyl)- 1 -phenyl- 1 -butyne hydrochloride (10.0 g, 26.9 mmol), isopropanol (600 mL), triethylamine (4.0 g, 40.3 mmol) and diphenylcyanocarbonimidate (8.0 g, 33.6 mmol) were combined and stirred at 25 °C for 1 hour. The precipitate material was filtered and washed with isopropanol to afford 6.2 g (48%) of white crystalline: mp 159 -I6I0C.
  • (+/-)-N-cyano-N'-[2-(3-cyclopentyloxy-4-methoxyphenyl)-4-phenylbut-3-ynyl] -0-(phenyl)isourea (6.2 g 12.93 mmol)
  • isopropanol 400 mL
  • anhydrous ammonia 400 mL
  • Most of the isopropanol was evaporated in vacuo, water was added, the mixture was extracted with ethyl acetate (3 x
  • (+/-)-N-cvano-N'-r2-(3-decyloxy-4-methoxyphenyl)-4-phenylbut-3-vnyll guanidine To a solution of (+/-)-N-cyano-N'-[2-(3-hydroxy-4-methoxyphenyl)-4-phenylbut-3- ynyl]guanidine (70 mg 0.21 mmol) in dimethylformamide (50 mL) was added 1- iododecane (62 mg 0.23 mmol) and potassium carbonate (32 mg 0.23 mmol), respectively, and the resulting mixture was stirred at 25oC for 18 h.
  • Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below:
  • a compound of Formula (I), (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion- wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules.
  • the wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
  • the wet granules are then dried in an oven at 140°F (60°C) until dry.
  • the dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.
  • a pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections (to 100 mL). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne de nouveaux antagonistes de récepteurs du peptide de libération de la gastrine (GRP). L'invention concerne également des procédés d'utilisation de ces composés pour produire un effet antagoniste sur les récepteurs du GRP. La présente invention concerne en outre la synthèse de ces composés.
PCT/US1999/018469 1998-08-14 1999-08-13 Ligands de récepteurs du peptide de libération de la gastrine WO2000009116A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9660198P 1998-08-14 1998-08-14
US60/096,601 1998-08-14

Publications (1)

Publication Number Publication Date
WO2000009116A1 true WO2000009116A1 (fr) 2000-02-24

Family

ID=22258148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018469 WO2000009116A1 (fr) 1998-08-14 1999-08-13 Ligands de récepteurs du peptide de libération de la gastrine

Country Status (1)

Country Link
WO (1) WO2000009116A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388126B2 (en) 2012-07-19 2016-07-12 Drexel University Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252861A (en) * 1962-06-25 1966-05-24 Ciba Geigy Corp Antihypertensive cinnamyl guanidine compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252861A (en) * 1962-06-25 1966-05-24 Ciba Geigy Corp Antihypertensive cinnamyl guanidine compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAMILLERI P.: "Chromatographic separation of beta-substituted 3-(3,4-dihydroxyphenyl)alanine derivatives", J. OF CHROMATOGRAPHY, vol. 523, 1990, pages 300 - 304, XP002923493 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388126B2 (en) 2012-07-19 2016-07-12 Drexel University Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
US9889102B2 (en) 2012-07-19 2018-02-13 Drexel University Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
US10314795B2 (en) 2012-07-19 2019-06-11 Drexel University Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases

Similar Documents

Publication Publication Date Title
JP5001505B2 (ja) 新規チオウレア誘導体およびこれを含有する薬学的組成物
SU1380614A3 (ru) Способ получени производных арилтиазолов или их хлористоводородных или бромистоводородных солей
TW200808734A (en) Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity
AU2007318092B2 (en) Calcium receptor modulating agents
JPH0220639B2 (fr)
OA11665A (en) Substituted phenyl derivatives, their preparation and use.
TW200403210A (en) Benzamide derivatives
IL132107A (en) Substituted phenyl derivatives, their preparation and use
JP2008515998A (ja) 化合物
CA2548849A1 (fr) Inhibiteurs de phenylamide et de pyridylamide de la beta-secretase, traitant la maladie d'alzheimer
JPH09188677A (ja) 医薬有効物質としての置換されたイミダゾリジン− ２，４− ジオン− 化合物
TW201043603A (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
CA2546142A1 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
US11236055B2 (en) Non-systemic TGR5 agonists
US6713473B1 (en) Tricyclic compounds
WO1999032466A1 (fr) Derives de benzenesulfonamide substitues et leur utilisation pharmaceutique
WO1999062892A1 (fr) Composes d'aminoazole
WO2000009115A1 (fr) Ligands de recepteurs de grp
NO137825B (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive tetrazolsubstituerte kromonderivater
MXPA02001207A (es) Abridores de canal de potasio.
CA3136725A1 (fr) Inhibiteurs de liaison cd40-cd154
WO2000009116A1 (fr) Ligands de récepteurs du peptide de libération de la gastrine
KR20080023758A (ko) 비만 및 관련 질환의 치료를 위한 신규한 아미노산 유도체
CA2177960A1 (fr) Nouveau derive de benzodiazepine
WO1997010214A1 (fr) Nouveaux derives d'acide phenylacetique et compositions medicinales les contenant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase